1. Introduction {#s0005}
===============

Phenylketonuria (PKU, OMIM \#[261600](261600){#ir0005}) is a classic example of an inborn error of metabolism, treatable with careful dietary management with a good clinical outcome. Classical PKU is caused by the deficiency of phenylalanine hydroxylase (PAH, EC 1.14.16.1) resulting in accumulation of excess phenylalanine (Phe) from dietary protein and causing the condition of hyperphenylalaninaemia (HPA), which is the main cause of neurological disturbances and intellectual disability in cases of untreated PKU \[[@bb0005]\]. While in unaffected individuals the Phe levels do not exceed 120 μmol/L (usually lower) \[[@bb0010]\], the safe and recommended values for those with PKU have been generally accepted to be three- to fivefold higher, depending on age.

Despite the fact that this treatment has been available for decades, adherence to recommended dietary restrictions has been always an issue of concern, as everyday maintenance of the diet together with social and economic issues may cause deviations from the ideal practice.

In 2017, European guidelines for the diagnosis and management of patients with PKU were agreed upon and published after substantial work of a group of experts \[[@bb0015],[@bb0020]\]. National guidelines of treatment, diagnostics and management of PKU had already been approved in Estonia in 2012 \[[@bb0025]\], providing approximately similar suggestions (See [Table 1](#t0005){ref-type="table"} for comparison \[[@bb0015], [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040]\]). It is currently unclear how well these recommendations have been implemented by the PKU patients and their families in Estonia.Table 1Recommendations for follow-up of Phe values in PKU patients according to Estonian \[[@bb0025]\], European \[[@bb0020]\], US \[[@bb0030],[@bb0040]\] and Australian \[[@bb0035]\] guidelines.Table 1Age groupRecommended highest Phe value according to Estonian (EST) guidelines (μmol/L)Recommended frequency for dietary follow-up - ESTRecommended highest Phe value according to European (EU) guidelines (μmol/L)Recommended frequency for dietary follow-up - EURecommended highest Phe value according to United States (US) guidelines (μmol/L)Recommended frequency for dietary follow-up - USRecommended highest Phe value according to Australian guidelines (μmol/L)0--2 y0--12 months -- 4; 2400--12 months- weekly3600--12 months- weekly3600--12 months- weekly3601--2 y − 240 (max 360)1--2 y -- twice per month1--2 y -- twice per month1--2 y -- twice per month2--12 y240 (max 360)2--6 y -- monthly360Twice per month360Once to twice per month3607 -12y -- 4 to 6 times yearly12--18 y360 (max 600)4 to 6 times per year600Monthly360Monthly500Adult (18+ y)360 (max 600)600Monthly360Monthly500

Since 2010, all results of any biochemical analysis performed in the United Laboratories of Tartu University Hospital (UL-TUH) have been recorded in a unified electronic laboratory information management system (LIMS), enabling an overview of all analyses preformed in every patient (incl. Phe measurements). Herewith we have created and analysed a sub-database from LIMS to obtain a generalized overview of the maintenance of dietary therapy and established practice of medical observation of Estonian PKU patients.

2. Material and methods {#s0010}
=======================

2.1. The database of PKU and HPA patients {#s0015}
-----------------------------------------

We created a sub-database of all available entries for the period 2010 to March 2018 from the general LIMS database available for any diagnostic analysis performed in UL-TUH, concerning all Estonian patients diagnosed with PKU or other forms of HPA. This database included the following fields: name, personal ID-code, date of sample collection, age at the moment of sample collection, assignment to age group at the moment of sample collection, Phe value in dried blood spot (either mg/dL or μmol/L), genotype, phenotype, diagnosis time (either from the newborn screening or late diagnosis in case of persons born before 1993), and assessment of educational level ([Table 2](#t0010){ref-type="table"}).Table 2Genotype, phenotype and Phe value data of Estonian PKU patients included in the study.Table 2Patient codeGenotypePhenotypeDiagnosedEducation level (ISCED 2011) or current educationPre-treatment max Phe μmol/LTotal entriesmin Phe μmol/Lmax Phe μmol/LPhe median abs μmol/LBHp.R408W/p.R408WClassicalScreening4158514366817648DJp.R408W/p.R408WClassicalScreeningPreschool age154311420570181DIp.R408W/p.R408WClassicalScreeningPreschool age138021261866193DCp.R408W/c.1315 + 1G \> AClassicalScreeningAssisted education262335541399551BGp.R408W/p.R408WClassicalScreening6154326333831562COp.R408W/c.1315 + 1G \> AClassicalScreeningNormal school144628754957182CKp.R408W/p.R408WClassicalScreeningNormal school1137493871414775CPp.R408W/c.1315 + 1G \> AClassicalScreeningNormal school207711054690107DOp.R408W/p.R408WClassicalScreeningPreschool age1313896694177BCp.R408W/p.R408WClassicalLate diagnosed2NA142221235602DBp.R408W/p.R408WClassicalScreeningNormal school1616103541520551DLp.R408W/p.R261QBH4-sensitiveScreeningNormal school14712923674266DGp.R408W/p.R261QClassicalScreeningPreschool age153212234593164BNp.R408W/p.D222\*ClassicalScreening31405125931066969AFp.R408W/p.R408WClassicalLate diagnosed1890141010954CBp.R408W/p.A300SBenign HPAScreening4NA5115254133CAp.R408W/NDMildScreening429122200678345BLp.R408W/p.I306VMildScreening640040133432227ANp.R408W/p.R408WClassicalLate diagnosed2NA413821162781BEp.R408W/p.R408WClassicalLate diagnosed114521254751119BBp.R408W/p.R408WClassicalLate diagnosed3NA10519981514BJp.R408W/p.R252WClassicalLate diagnosed12305184361368787CDp.R408W/p.R408WClassicalScreening4182219925923327AAp.R408W/p.R408WClassicalLate diagnosed3NA94541197454BIp.R408W/p.R408WClassicalScreening41017176541118506AMp.R408W/p.R408WClassicalLate diagnosed1NA3454636173ABp.R408W/p.R408WClassicalLate diagnosed3NA4154726375BMp.R408W/p.R408WClassicalScreening51762246301368884CLp.R408W/p.R408WClassicalScreeningNormal school14111454799179DPp.L48S/p.E280KClassicalScreeningPreschool age314233917992CGp.R408W/p.A300SBenign HPAScreeningNormal schoolNA5157200163DDp.R408W/p.L48SBH4-sensitiveScreeningNormal school72019654896248BFp.R408W/p.S349PClassicalLate diagnosed6216010954896424CFp.R408W/p.E280KClassicalScreeningNormal school218598611302569DAp.L48S/p.E280KClassicalScreeningNormal school154411954769182CNp.R408W/p.R408WClassicalScreeningNormal school22168173811448DNp.R408W/p.R408WClassicalScreeningPreschool age571938786101BDp.R408W/c.1315 + 1G \> AClassicalLate diagnosed2NA2115011681159CEp.R408W/p.R408WClassicalScreeningNormal school2149232581023551ADp.R408W/p.R408WClassicalLate diagnosed1NA9206757437DEp.R408W/p.R408WClassicalScreeningPreschool age2403311891485CJp.R408W/p.R408WClassicalScreeningNormal school18467954957357DMp.R408W/p.R408WClassicalScreeningPreschool age60977756493CMp.R408W/p.R261QBH4-sensitiveScreeningAssisted education150111854790347AHp.R158Q/c.1315 + 1G \> AClassicalLate diagnosed2NA30345914533DQp.R408W/p.R408WClassicalScreeningPreschool age1213241259036CIp.R408W/p.E280KClassicalScreeningNormal school23559454880412BKp.R408W/p.L48SClassicalScreening4121136297714490BAp.R408W/p.R408WClassicalLate diagnosed3NA8654490150ALp.R408W/p.R408WClassicalLate diagnosed1NA1890890890DFp.R408W/p.I65TClassicalScreeningPreschool age22827552513139AJp.R408W/p.R408WClassicalLate diagnosed3NA24541108932DKp.R408W/p.P281LClassicalScreeningPreschool age2785158541174559AKp.R408W/p.R408WClassicalLate diagnosed118456176611490CHp.R408W/p.R408WClassicalScreeningNormal school273014285733552AIp.R408W/p.R408WClassicalLate diagnosed2NA701396997DHp.R408W/p.E390GBH4-sensitiveScreeningPreschool age3515154696224AGp.R408W/p.R408WClassicalLate diagnosed1NA123041168562AEp.R408W/p.R408WClassicalLate diagnosed31616149541616642ACp.R408W/p.R408WClassicalLate diagnosed2NA95791392756Medians:4154848394[^1]

The initial created database included 4290 entries from 69 patients. All patients were carefully classified by genotype/phenotype data and these results have been previously published \[[@bb0045]\]. All data from individuals with initially suspicious samples obtained by newborn screening, but not confirmed with HPA, were excluded, as well as Phe levels confirming the newborn screening results and data obtained from a Phe loading/cofactor tetrahydrobiopterin (BH~4~) test. The information about BH~4~ responsiveness testing has been published earlier \[[@bb0045]\]. As the objective of the study was to draw insight into the quality and trajectory of ongoing therapy, nine of the subjects and all of their blood Phe values were excluded from the database due to late diagnosis associated with deep intellectual disability and/or refusal of treatment. The final database for further analysis therefore consisted of 4236 entries from 60 patients.

The following age groups were created: ≤1 year; 1 year 1 day to 2 years; 2 years 1 day to 6 years; 6 years 1 day to 12 years; 12 years 1 day to 18 years; \>18 years (for simplicity further referred to as: 0--1 y, 1--2 y, 2--6 y, 6--12 y, 12--18 y, 18+ y, respectively). The age group 0--1 y contained 662 entries from 19 patients, 1--2y contained 548 entries from 19 patients, 2--6 y contained 1140 entries from 20 patients, 6--12y contained 470 entries from 19 patients, 12--18 y contained 477 entries from 16 patients and the adult group 18+ y contained 933 entries from 27 patients. We had only one patient (AE) with maternity in the adult group 18+ y; she had two pregnancies with strict diet during this study period. Median, maximum and minimum Phe values were counted for each group. All entries with Phe values above maximum recommended value of 360 μmol/L in case of patients up to 12 years of age and higher than 600 μmol/L in case of patients older than 12 years of age were counted and the ratio of entries elevating the recommended level was calculated.

2.2. Phenylalanine measurement {#s0020}
------------------------------

During the period under observation, two different methods of Phe measurement from dried blood spots (BS) collected on filter paper (Schleicher and Schuell filter paper No 2992) were used. These included the modified McCaman and Robins quantitative fluorescence-based method measuring ninhydrin-phenylalanine complex enhanced by L-leucyl-L-alanine dipeptide \[[@bb0050]\] measured on FluoroScan™ (Labsystems Oy, Helsinki, Finland) device using Labsystems neonatal phenylalanine kit (no. 6199 897) and LC-MS/MS tandem mass spectrometry on Waters Aquity™ Ultra Performance LC device using ChromSystems MassChrom® Amino Acids and Acylcarnitines from Dried Blood kit (order nr 55,000) applying neutral loss scan 120 detection, according to the methods provided by the manufacturer. Both methods were regularly evaluated for inner quality as well as by external quality controls and before the launch of the extended newborn screening in 2015 with LG-MS/MS, both methods were used in parallel for a couple of months and exhibited good correlation. Due to the switch in analytical methods in 2015 from fluorescence measurement with FluoroScan to LC-MS/MS analysis, Phe values were presented in different units. However, in order to unify the results, the values presented in mg/dL were converted (by multiplying by a factor of 60.54) to obtain unified numeric values. As the values obtained by FluoroScan were not distinguished if lower than 1 mg/dL and higher than 25 mg/dL (shown as \<1 and \>25 mg/dL in the original database, respectively), said values were substituted with 0.9 and 25.1 mg/dL, and further converted to μmol/L to enable analysis with numeric values. In order to avoid distortion in data analysis, we used median values in calculations instead of mean values, as the lower (\<1 mg/dL) and higher (\>25 mg/dL) result values obtained by McCaman-Robins method would have introduced too big error into finding the mean values, but were correctly interpreted in counting median values.

2.3. Assessment of educational level {#s0025}
------------------------------------

Data about the educational level of the PKU patients were obtained during regular visits to outpatient clinic from the patients and/or their families. The patients younger than 18 y of age were assigned as "normal school", "assisted education" or "preschool age". In the patients older than 18 y of age, educational levels were evaluated according to ISCED 2011 scaling \[[@bb0055]\].

2.4. Data analysis {#s0030}
------------------

Data from LIMS were selected and analysed using Microsoft Excel software.

2.5. Compliance with ethical standards {#s0035}
--------------------------------------

This study was approved by Research Ethics Committee of the University of Tartu (approval date 21.09.2015 number 251/T-6).

3. Results {#s0040}
==========

Among all of Estonian PKU patients, the median of medians of Phe values during the observed period was 394 μmol/L, reflecting that approximately half of the patients were able to sustain the recommended dietary treatment for half of the measurement instances ([Table 2](#t0010){ref-type="table"}). The summary of the average Phe levels for the whole cohort is given in [Fig. 1](#f0005){ref-type="fig"} (individual averages are presented in Supplementary Fig. 1). Only four of the 60 patients (patients AF, BA, CG, DP,) never exceeded the recommended Phe level during the entire evaluation period. Of these, only patient CG has the benign PKU phenotype, with the other three having classical PKU. As this assessment took into account all entries without discrimination of the age of the patient, the regularity of observations, or concomitant health problems, we therefore next split the database into more distinct six age groups.Fig. 1Average Phe values of all Estonian PKU patients of ages 0 to 18 years together during 2010 to 2018.Fig. 1

All values of blood spot Phe analyses presented in relation to the recommended cut-off values in Estonia (see [Table 1](#t0005){ref-type="table"}) are shown in a diagram ([Fig. 2](#f0010){ref-type="fig"}). All data are presented in groups by age of the patients. [Fig. 3](#f0015){ref-type="fig"} shows the percentage of patients in an age group with median Phe values falling below the national recommendation levels of the respective age.Fig. 2All entries (*N* = 4236) of blood spot Phe values of Estonian PKU/HPA patients in LIMS of UL-TUH are shown on a diagram regarding recommended limits as percentage along age groups. The diagram presents generalized overview of adherence to dietary recommendations in particular age groups and draws out the proportion of samples in well-managed patients and cases with lower dietary adherence.Fig. 2Fig. 3Median blood spot Phe values of Estonian PKU/HPA patients (*N* = 60) are shown in the diagram as percentage fitting under the recommended national values according to age groups. Here the medians of gathered blood spot values of each patient are assembled into the graph to present the proportion of well-managed individual diet among every age group.Fig. 3

Results of the age group of 0--1 y (19 patients, Estonian reference value 240 μmol/L; European reference value 360 μmol/L -- (results given in brackets); Table 1 Suppl). For 79% of all measurements and 95% of the patients, the median Phe values were within the range of the nationally-recommended levels ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). There were three (five) patients (CO, DP, DE), all with classical PKU, whose Phe value never exceeded the recommended level, while for six (nine) patients the elevated levels occurred in \<10% cases of measurement, likely referring to occasional fluctuations possibly due to infections or random uncontrolled ingestions of unchecked products. In three patients, the elevated levels occurred between 10 and 20% of measurements, while four patients exhibited elevated levels in 50, 44 and 35% of measurements, which may indicate that the latter families were not able to consistently follow the advised dietary instructions. The median number of samples arriving to the laboratory was 35, which is lower than the recommended weekly frequency.

Results of the age group of 1--2 y (19 patients, Table 2 Suppl). These results exhibited some change compared to 0--1 y: for 77% of all measurements and 84% of the patients, the median Phe values were in the range of the nationally-recommended levels ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). The median of medians of Phe values remained at 224 μmol/L, suggestive of generally acceptable adherence to diet. The group contained the same 19 patients as the 0--1 y cohort, however in only three patients (CP, DE, DN) did the Phe value exceed suggested recommendations (360 μmol/L) in no \>10% of measurements, while six patients exhibited elevated levels in \>25% of the measurements, including two patients whose Phe values did not fit into the recommended level for a single case during this age period. Similarly to the first age group, the median count of samples per patient was 32, being in good accordance with the fortnightly recommendation.

Results of the age group of 2-6y (20 patients, Table 3 Suppl).For 63% of all measurements and 70% of the patients, the median Phe values were in the range of the nationally-recommended levels ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). The median of medians of Phe values was 285 μmol/L, but on the background of drastically diverging individual scores. In only four (patients DA, DE, DF, DH) did elevations above the recommendation (360 μmol/L) occur in \<10% of cases; three of them having classical PKU and one has BH~4~-sensitive PKU. In three patients, the elevated levels occurred between 10 and 25% of measurements (patient CO, CP, DG), and all the remaining 13 patients exceeded the level more frequently, with four of them exceeding the level in 90--100% of entries, reflecting severe difficulties in keeping the diet. Additionally, the sampling frequency deviates substantially.

Results of the age group of 6--12 y (19 patients, Table 4 Suppl). For 46% of all measurements and 43% of the patients, median Phe values were in the range of the recommended levels ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). The tendency for elevated Phe increased as shown earlier (recommended 360 μmol/L). For only three cases of 19 patients was an elevated Phe level observed in \<10% of entries, including one patient with mild HPA. Simultaneously, 11 of the patients had Phe increase above 360 μmol/L in \>50% of analysed samples. This high ratio of elevated results may refer to difficulties in maintaining the dietary regimen the in rapidly changing social context of early school years. Blood spot sampling frequency also declined in this age group, as the median number of samples per patient was only 14 during six years.

Results of the adolescent group of 12--18 y (16 patients, Table 5 Suppl). For 79% of all measurements and 59% of the patients, the median Phe values were in the range of the nationally-recommended levels ([Fig. 3](#f0015){ref-type="fig"}). The distribution of elevated values among patients was notably more variable than in the younger groups: while in half of the patients, the ratio of elevated Phe samples remained in the limits from 0 to 40% of measured samples; another half exceeded the recommended level in more than half of the measured cases. Here we also observed relatively low activity in sending blood samples, as the median count was 14.5.

In the adult group of 18+y (27 patients, Table 6 Suppl). For 68% of all measurements and 57% of the patients, the median Phe values were in the range of the nationally-recommended levels ([Fig. 3](#f0015){ref-type="fig"}). For three patients (AF, BA, BL) the Phe value never exceeded the recommended level, two of them having late-diagnosed classical PKU phenotype, and one with a mild HPA; in five cases it happened only once or twice (AI, AK, AM, BE; all with classical phenotype, late diagnosis and p.Arg408Trp / p.Arg408Trp genotype; and BK from screening, classical phenotype), not taking into account those who presented their samples very rarely. Still, in 11 patients the elevated values were present in more than half of the measurements. Wide differences occurred in the frequency of sending control samples: from a single sample during the whole period to constant monitoring with 100--150 samples presented, resulting in a frequency of sampling of up to 14 to 18 times per year.

4. Discussion {#s0045}
=============

Maintaining acceptable blood Phe levels in PKU patients as suggested in national guidelines \[[@bb0025],[@bb0030]\] or more widely agreed among international consortiums \[[@bb0015],[@bb0040]\] can be burdensome for families \[[@bb0060]\], even though it is clear that adherence to these recommendations is important for avoiding undesirable neuropsychiatric symptoms as well as intellectual disability \[[@bb0065],[@bb0070]\]. Our results from the Estonian cohort of PKU patients reflect the tendencies of gradually occurring deviation from the suggested recommendations over time ([Fig. 1](#f0005){ref-type="fig"}). Our data present results from each patient during the eight year period (Supplementary Fig. 1), enabling analysis of the characteristics of dietary management both at the individual and group level.

Previously, similar observations have been presented by Walter et al., 2002 \[[@bb0060]\], wherein about a quarter of all samples from ages 0--4 years and 5--9 years exceeded the recommended level. Similarly to Walter et al. \[[@bb0060]\], our results show that blood Phe concentration was not always maintained below the recommend value.

The adherence to the recommendations in younger age groups remains remarkably higher, while with the increase of age and in adolescence the results became increasingly divergent. A report involving data from ten European PKU centres has shown similar results, reflecting that these same obstacles are to be faced in any country and population \[[@bb0075]\]. Ahring et al., 2011, has demonstrated that blood Phe concentrations increase with age, and we observed a similar tendency ([Fig. 1](#f0005){ref-type="fig"}), although we also observed a small decrease in average Phe concentrations at the age of 14 to 16 years that is not fully understood. One possible explanation is that dietary control in adolescents may be better than reported previously \[[@bb0075]\]. In comparison with the work of Jurecki et al., 2017 \[[@bb0080]\], our data also show better compliance with the recommendations in our adolescent patients than the pre-adolescence age group.

Our approach in the current study was to observe each of the patients during the entire available period, up to eight years. The median Phe value for either the whole period or selected age gives a better understanding of a particular patient\'s general adherence to dietary management if fluctuations in Phe over the recommended level remain sporadic. However, if the median value is observed to be higher than the recommendation, the family may warrant closer attention and observation.

During the first year of life, only a few families were not able to follow the dietary requirements, while most of the patients had only single occurrences of elevated Phe levels that were explainable by occasional infections or random dietary indiscretions. In general, our results depict the willingness of the families to follow the requirements as well as good level of clinical advice and dietary consultation.

The age group from 1 to 2 years already exhibited already more deviation from desirable Phe levels, though the general adherence rate still remained acceptable, as the median of median Phe values among the whole group remained 224 μmol/L, referring to the fact that more than half of the patients could maintain the desired levels in more than half of cases. This can still be considered reflective of good of parental control and family education. The results from the group of 2 to 6 year old children diverged, and the number of patients with only a few exceeded Phe values decreased, though the median of medians of Phe values remained lower than the recommended level. The next age group (6 to 12 y) faces the change of lifestyle and social activity: social pressure from school and more challenges in everyday life. Simultaneously, it may reflect the inability of school catering to comply with the needs of the children with special requirements. In the group of adolescents (12--18 y), differences in the regularity of follow-up, i.e. sample collection, become especially obvious. In spite of the relaxed recommendation of 600 μmol/L Phe level, nearly half of the patients exhibited elevated Phe levels in more than half of the cases. The same phenomenon is true about the adult group. Here we have not isolated the cases where female patients have become pregnant and therefore had stricter regulations of the diet. One reason for the difficulty of maintaining the Phe levels in blood in the observed patients may be the severity of particular *PAH* mutation, as the p.Arg408Trp variation vastly predominant in Estonian population \[[@bb0045]\] completely abolishes PAH activity, if present in homozygous state.

We have also focused on the data from patients with exceedingly elevated Phe levels: nine patients had a median Phe level of 720 μmol/L or higher. Phenotypically, they all exhibit the classical PKU phenotype, which is in accordance with their genotype, harbouring the predominant p.Arg408Trp variation of the *PAH* gene in one or both of the alleles, and in compound heterozygotes the second allele (p.Asp222\*, p.Arg252Trp, c.1315+1G\>A) has been shown to have a deleterious effect on PAH activity. Six of these patients had been diagnosed late, before the launch of national screening program, providing an explanation to their inability to adhere to the recommendations, as elevated Phe during their infancy had already caused cognitive damage. However, three remaining patients were not diagnosed late and exhibited normal progress in education (remarkably, patient BM has even succeeded achieving level 5 educational stage according to ISCED 2011 standards). This last example confirms the importance of early diagnosis and initiation of treatment, where even a relaxed attitude towards the diet in adolescence has not contributed negatively to educational achievement.

As would be presumed, the eight patients with mild or benign HPA, as well as with BH~4~-sensitive PKU, exhibit good adherence to the diet, with median Phe values clearly below recommended reference value, though still with occasional elevated fluctuations in case of patients DD and CM.

The possibility, that there has been born a person with mild HPA without being registered and medically supervised is improbable since the introduction of the screening programme in 1993 \[[@bb0085]\]. However, we cannot exclude the option that there may exist some adult patients born before 1993 with mild HPA who have never reached the scope of medical doctors. While Estonian PKU cohort has been shown to be genetically very homogenous \[[@bb0045]\], this chance is fortunately very low.

Moreover, during the last decades we have successfully implemented regular nutrition-practicing camps and courses organised by the Estonian PKU Association, an NGO bringing together families including a member with PKU. We have also been able to include regular consultations from a dietician since early infancy, and we presume this assistance may be a key factor for the families to adhere successfully to the recommendations.

The variability of dietary adherence was not connected to the severity of the genotype, as 20 of the patients with median Phe values under the recommended reference have the *PAH* genotype fully depleting PAH activity (14 of them are homozygotes for the p.Arg408Trp variant). However, the same severe mutations occurred in the patients with poor adherence. Surprisingly, five of the late diagnosed patients with low educational results manifest really well-controlled Phe levels, probably referring to well established family support or institutional care.

There are only four patients (AF, BA, CG, DP) in our cohort whose Phe values have been constantly under the reference value: one with benign HPA, other with the classical PKU version, while two of the latter belong to the group of late-diagnosed patients.

As another observation, the PKU patients of the same family (patients CI and CF; DA and DP; BC and AG) exhibit usually very similar Phe level patterns; in one pair (CL and CH) the divergence was greater and, interestingly, in one pair the late-diagnosed sibling (BA) has excellent dietary adherence, while his sister (BI) with a more timely diagnosis demonstrated more fluctuations and higher median Phe value.

There are only two centres for treating PKU in Estonia and some patients must travel a long distance for regular clinic visits. However, nowadays patients and/or their parents are may obtain Phe samples locally and send them to the laboratory by courier or by mail, receiving results mostly by email and occasionally by telephone call. We did not analyse our data by geographical distribution of the patients, though Freehauf et al., 2013 \[[@bb0090]\], has shown that geographic access to care does not impact control of Phe levels, but it does affect the number of monitoring samples sent to the clinic. We did observe that the patients with good adherence to the diet also had a tendency to perform regular sampling, and this should not be dependent on their place of residence.

5. Conclusions {#s0050}
==============

We have provided insight into the dietary control measurements of an Estonian PKU patient cohort over an eight year period. These data have enabled our observation of both individual adherence to dietary management as well as displaying general tendencies characteristic to each age group.

Overall, we observed that during two first years of life, the families show good dietary adherence and follow the recommendations, with the exception of only a few families. However, the number of the cases of elevated Phe values subsequently increases with age, especially during early school age (6 to 12 y). In adolescence the picture slightly improves, but the relaxed dietary threshold for adults is still frequently crossed by most patients.

The ability to maintain the diet among the patients with classical PKU phenotype shows great variability, though, surprisingly, good results were seen among a few late-diagnosed patients, even those with poor cognitive functioning.

Our data reflect similar tendencies observed previously in other studies from different PKU management centres, an increase in cases of elevated Phe levels is seen in parallel with age.

The following are the supplementary data related to this article.Supplementary Fig. 1Individual yearly average phenylalanine (Phe) values of Estonian phenylketonuria patients.Supplementary Fig. 1Supplementary Table 1Maximal, minimal, and median values of Estonian PKU patients of age 0-1y, number of entries and amount of test samples exceeding recommended national and EU Phe values.Supplementary Table 1Supplementary Table 2Maximal, minimal, and median values of Estonian PKU patients of age 1-2y, number of entries and amount of test samples exceeding recommended national Phe values.Supplementary Table 2Supplementary Table 3Maximal, minimal, and median values of Estonian PKU patients of age 2-6y, number of entries and amount of test samples exceeding recommended national Phe values.Supplementary Table 3Supplementary Table 4Maximal, minimal, and median values of Estonian PKU patients of age 6-12y, number of entries and amount of test samples exceeding recommended national Phe values.Supplementary Table 4Supplementary Table 5Maximal, minimal, and median values of Estonian PKU patients of age 12-18y, number of entries and amount of test samples exceeding recommended national Phe values.Supplementary Table 5Supplementary Table 6Maximal, minimal, and median values of Estonian PKU patients of age \>18y, number of entries and amount of test samples exceeding recommended national Phe values.Supplementary Table 6
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